Grifols-Backed Biotech Sees Early Promise With Alzheimer's Vaccine

Phase I results for Araclon Biotech's Alzheimer's disease vaccine, ABvac40 – the only vaccine data presented at this year's Alzheimer's Association International Conference – warrant further exploration of this innovative approach to the disease.